Am. J. Respir. Crit. Care Med., Volume 157, Number 3, March 1998, 743-747

Exposure to Commonly Prescribed Drugs and the Etiology of Cryptogenic Fibrosing Alveolitis
A Case-Control Study

RICHARD HUBBARD, ANDREA VENN, CHRIS SMITH, MARIE COOPER, IAN JOHNSTON, and JOHN BRITTON

Division of Respiratory Medicine, City Hospital; and Department of Respiratory Medicine, Queen's Medical Centre, University Hospital, Nottingham, United Kingdom

Cryptogenic fibrosing alveolitis is an interstitial lung disease of unknown etiology. Since pulmonary fibrosis is a recognized, if rare, complication of certain drug exposures, including antidepressants, betablockers, antibiotics, anticonvulsants, and nonsteroidal antiinflammatory drugs (NSAIDs), we tested the hypothesis that exposure to these drugs might contribute to the etiology of cryptogenic fibrosing alveolitis. Lifetime drug exposure data were collected from general practitioner records for 141 cases of cryptogenic fibrosing alveolitis and 246 age-, sex-, and community-matched control subjects from the Trent region of England. Additional data on lifetime smoking habits were obtained by postal questionnaire. The odds of disease in relation to ever exposure to antidepressants, betablockers, antibiotics, anticonvulsants, and NSAIDs were calculated by conditional logistic regression. For drug groups significantly associated with cryptogenic fibrosing alveolitis, subset analyses were performed to investigate the effects of individual drugs. Cryptogenic fibrosing alveolitis was associated with exposure to antidepressants (odds ratio [OR] 1.79 [95% CI 1.09-2.95], p = 0.022) and specifically to imipramine (OR 4.79 [1.50-15.3], p = 0.01), dothiepin (OR 2.37 [0.99-5.69], p = 0.05), and mianserin (OR 3.27 [1.11-9.61], p = 0.03). The magnitude of the overall effect of antidepressants was not changed by excluding all drug exposures within the 5 yr preceding the diagnosis of cryptogenic fibrosing alveolitis (OR 1.62 [0.94-2.77], p = 0.081), nor were the strong individual effects of imipramine (OR 5.72 [1.54-21.2], p = 0.009) and dothiepin (OR 5.58 [1.12-27.8], p = 0.036). These estimates were not appreciably affected by controlling for smoking history. The attributable risk for antidepressant exposure was in the region of 9-14%. No significant association was noted between cryptogenic fibrosing alveolitis and the four other drug groups in the primary hypothesis. The results of this study suggest that some antidepressant drugs can cause cryptogenic fibrosing alveolitis.

This article has been cited by other articles:

				K. R. Flaherty, J. A. Mumford, S. Murray, E. A. Kazerooni, B. H. Gross, T. V. Colby, W. D. Travis, A. Flint, G. B. Toews, J. P. Lynch III, et al. Prognostic Implications of Physiologic and Radiographic Changes in Idiopathic Interstitial Pneumonia Am. J. Respir. Crit. Care Med., September 1, 2003; 168(5): 543 - 548. [Abstract] [Full Text] [PDF]

				T. Enomoto, J. Usuki, A. Azuma, T. Nakagawa, and S. Kudoh Diabetes Mellitus May Increase Risk for Idiopathic Pulmonary Fibrosis Chest, June 1, 2003; 123(6): 2007 - 2011. [Abstract] [Full Text] [PDF]

				M. Drent, S. Singh, A. P. M. Gorgels, D. M. Hansell, O. Bekers, A. G. Nicholson, R. J. van Suylen, and R. M. du Bois Drug-induced Pneumonitis and Heart Failure Simultaneously Associated with Venlafaxine Am. J. Respir. Crit. Care Med., April 1, 2003; 167(7): 958 - 961. [Abstract] [Full Text] [PDF]

				American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias . This Joint Statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS Board of Directors, June 2001 and by The ERS Executive Committee, June 2001 Am. J. Respir. Crit. Care Med., January 15, 2002; 165(2): 277 - 304. [Full Text] [PDF]

				Ph. Camus, P. Foucher, Ph. Bonniaud, and K. Ask Drug-induced infiltrative lung disease Eur. Respir. J., July 1, 2001; 18(32_suppl): 93S - 100s. [Abstract] [Full Text] [PDF]

				J. M. Harris, P. Cullinan, and J. C. McDonald Occupational Distribution and Geographic Clustering of Deaths Certified To Be Cryptogenic Fibrosing Alveolitis in England and Wales Chest, February 1, 2001; 119(2): 428 - 433. [Abstract] [Full Text] [PDF]

				M. Selman, T. E. King Jr., and A. Pardo Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy Ann Intern Med, January 16, 2001; 134(2): 136 - 151. [Abstract] [Full Text] [PDF]

				R. Hubbard and A. Venn Adult height and cryptogenic fibrosing alveolitis: a case-control study using the UK General Practice Research Database Thorax, October 1, 2000; 55(10): 864 - 866. [Abstract] [Full Text]

				S. C Bourke and H. Clague Review of cryptogenic fibrosing alveolitis, including current treatment guidelines Postgrad. Med. J., October 1, 2000; 76(900): 618 - 624. [Full Text]

				T. King Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment . International Consensus Statement Am. J. Respir. Crit. Care Med., February 1, 2000; 161(2): 646 - 664. [Full Text]